Abstract 3184
Background
Although nivolumab has been widely adopted as a treatment for advanced RCC, only a minority of pts benefit. We aimed to use radiomics as a predictive biomarker. By extracting quantitative information from serial imaging, this non-invasive method captures the spatial and temporal heterogeneity of tumors, more than tissue biopsy. We hypothesized to find an imaging correlate of host immune recognition, characterized by infiltration of the invasive tumor margin by immune effector cells, that would identify pts to benefit from nivolumab.
Methods
We retrospectively identified all advanced RCC pts treated with nivolumab at our institution from 2013-2017. Pts were labelled as responders (CR / PR / durable SD) or non-responders based on clinical data. For each pt, lesions were contoured from pre-treatment and first on-treatment CT scans. All lesions were manually contoured in tandem by two trained investigators. This information was used to train a radial basis function support vector machine classifier to learn a prediction rule to distinguish responders versus non-responders. The classifier was internally validated by 10-fold nested cross-validation.
Results
37 pts were identified. Excluded: imaging unavailable = 3, incompatible CT protocols = 7. 104 lesions were contoured from 27 pts. Median age 56 years, 78% male, 89% clear cell histology, 89% prior nephrectomy, 89% prior systemic therapy. 19 responders vs 8 non-responders. Lesions: 60% lymph nodes, 23% lung metastases, 17% renal/adrenal metastases. For the classifier trained on the baseline CT scans, 69% accuracy was achieved. For the classifier trained on the first on-treatment CT scans, 66% accuracy was achieved.
Conclusions
Based on preliminary computations, the radiomics signature could discriminate nivolumab responders from non-responders. Additional texture feature analysis with over 72 billion calculations is underway to improve the classifier performance to discriminate tumor responses to immunotherapy. External validation against the comprehensive patient dataset from the International Metastatic Renal Cell Cancer Database Consortium is planned.
Clinical trial identification
Legal entity responsible for the study
Dr Hao-Wen Sim and Dr Aaron Hansen.
Funding
Awarded $40,000 from peer-reviewed 2017 GUMOC Astellas Research Grant.
Editorial Acknowledgement
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4742 - Ki67 as an important predictor for Oncotype Dx Recurrence score risk groups in Early Breast cancer
Presenter: Fernando Namuche
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4697 - Genetic signatures always suggest undertreatment? Experience with PAM51
Presenter: Carolina Sales
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3158 - Significance of receptors expression, mitotic index and Ki67 in breast cancer patients with Nottingham Prognostic Index (NPI) poor prognosis score
Presenter: Mejri Nesrine
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3838 - Subgroup analyses of efficacy from a phase III study comparing SB3 (trastuzumab biosimilar) with reference trastuzumab in early breast cancer patients
Presenter: Javier Cortes Castan
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
715 - Autoimmunity and benefit from trastuzumab treatment in breast cancer: results from the HERA phase 3 trial
Presenter: Amir Sonnenblick
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2388 - Impact of hormone receptor status in HER2+ early breast cancer: a paradigm shift in the trastuzumab era
Presenter: Alexandre De Nonneville
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3742 - Sefety profile of subcutaneous trastuzumab in patients with HER2-positive early breast cancer: The french HERMIONE non-interventional prospective study
Presenter: jean-philippe Jacquin
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3647 - Real-life data on the cardiac toxicity of adjuvant fixed-dose subcutaneous trastuzumab in HER2-positive breast cancer.
Presenter: Rita De Sanctis
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3837 - Comprehensive evaluation of the pharmacokinetic profiles of SB3 and reference trastuzumab
Presenter: Xavier Pivot
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
1692 - The impact of neoadjuvant dual HER2 targeting with Pertuzumab and Trastuzumab on pathological complete response (pCR) rates: Kent Oncology Centre (KOC) experience
Presenter: Samantha Forner
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract